Complex dynamics of hepatitis B virus resistance to adefovir
نویسندگان
چکیده
منابع مشابه
Complex dynamics of hepatitis B virus resistance to adefovir.
UNLABELLED In patients with hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil administration selects variants bearing reverse transcriptase rtN236T and/or rtA181V/T substitutions in 29% of cases after 5 years. The aim of this study was to characterize the dynamics of adefovir-resistant variant populations during adefovir monotherapy in order to better understand the molecul...
متن کاملHepatitis B virus with primary resistance to adefovir.
The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to te...
متن کاملDynamics of hepatitis B virus resistance to lamivudine.
Lamivudine was the first approved inhibitor of hepatitis B virus (HBV) reverse transcriptase (RT). Lamivudine resistance develops in 53% to 76% of patients after 3 years of treatment. We extensively characterized the dynamics of HBV quasispecies variant populations in four HBV-infected patients who developed lamivudine resistance. Virological breakthrough was preceded by 2 to 4 months by the em...
متن کاملDoes pre-treatment with lamivudine prime for adefovir resistance of hepatitis B virus infection?
My recent leading article on silver-based products as antimicrobial agents was intended primarily to address microbiological issues such as bacterial susceptibility and the potential for the development of resistance to these products. Consequently, I did not consider the toxicological issues raised by Bayston et al. in their comment upon my article. Obviously, a heavy-metal cation such as silv...
متن کاملEvolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
BACKGROUND The efficacy of entecavir (ETV) monotherapy in treatment-experienced patients with chronic hepatitis B (CHB) is debatable. METHODS A total of 22 hepatitis B e antigen (HBeAg)-positive CHB patients who had shown viral breakthrough or suboptimal response with lamivudine (3TC) and adefovir disoproxil (ADV) therapy were treated with 1.0 mg of ETV. Clinical and virological parameters we...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hepatology
سال: 2008
ISSN: 0270-9139
DOI: 10.1002/hep.22634